Home › Research › Treatments
Curcuma longa-Derived Curcumin Nanoparticles in Experimental Models of Alzheimer’s Disease: A Formulation-Based Approach
Pasrija Kanika, Alka Patel, Bichitrananda Tripathy. Probecell Science, 2026-01-11
Topic: Amyloid, tau and blood-test diagnosis
Alzheimer's disease (AD) is a neurodegenerative disorder involving the amyloid-β plaque deposition, tau pathology, synaptic dysfunction, and impairment in cognition. Despite years of research, all current treatment modalities are symptomatic rather than effective in preventing disease progression. Curcumin, a natural polyphenol extracted from the plant Curcuma longa, possesses potent antioxidant, anti-inflammatory, and anti-amyloid features, but its therapeutic application is hampered by inadequate aqueous solubility, low permeability across the blood-brain barrier (BBB) and poor systemic bioavailability. The goal of this study is to innovate and evaluate the neuroprotection of curcumin-loaded polymeric nanoparticles in Alzheimer\'s disease experimental models. The particle size of formulation F6 was optimal, the polydispersity index was minimised, the efficiency of encapsulation maximised, and a long-term drug release profile was demonstrated. Pharmacological studies in vivo revealed that curcumin nanoparticles significantly improved cognitive function, compared to free curcumin, as evidenced by Morris’s water maze, Y-maze, and novel object recognition tests. Histopathological examination confirmed a significant reduction in amyloid plaque burden and a preserved neuronal architecture in the nanoparticle-treated group. Conclusion: Curcumin administered via nanoparticles would be an effective multi-targeted therapeutic approach against AD.
Key findings
- The particle size of formulation F6 was optimal, the polydispersity index was minimised, the efficiency of encapsulation maximised, and a long-term drug release profile was demonstrated.
- Pharmacological studies in vivo revealed that curcumin nanoparticles significantly improved cognitive function, compared to free curcumin, as evidenced by Morris’s water maze, Y-maze, and novel object recognition tests.
- Histopathological examination confirmed a significant reduction in amyloid plaque burden and a preserved neuronal architecture in the nanoparticle-treated group.
Why it matters
In experimental Alzheimer's models, curcumin-loaded polymeric nanoparticles improved cognitive test performance compared with free curcumin and reduced amyloid plaque burden with preserved neuronal architecture. These are animal and histopathological findings, so they do not establish a treatment or cure for people.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 27/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Probecell Science) |
| Journal's citation record | 0 / 4 | Probecell Science: journal h-index 2 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 0 / 4 | Last-listed author Bichitrananda Tripathy: h-index 4 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Guru Jambheshwar University of Science and Technology: institution h-index 200 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 27 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Kanika, P., Patel, A., & Tripathy, B. (2026). Curcuma longa-Derived Curcumin Nanoparticles in Experimental Models of Alzheimer’s Disease: A Formulation-Based Approach. Probecell Science. https://doi.org/10.65807/prob.sci.2025.2.2.4
Vancouver
Kanika P, Patel A, Tripathy B. Curcuma longa-Derived Curcumin Nanoparticles in Experimental Models of Alzheimer’s Disease: A Formulation-Based Approach. Probecell Science. 2026. doi:10.65807/prob.sci.2025.2.2.4.
BibTeX
@article{kanika2026-329f85f8,
author = {Kanika, Pasrija and Patel, Alka and Tripathy, Bichitrananda},
title = {{Curcuma longa-Derived Curcumin Nanoparticles in Experimental Models of Alzheimer’s Disease: A Formulation-Based Approach}},
journal = {Probecell Science},
year = {2026},
doi = {10.65807/prob.sci.2025.2.2.4},
url = {https://doi.org/10.65807/prob.sci.2025.2.2.4}
}
Related studies in Treatments
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.